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INTRODUCTION
Sickle cell disease (SCD) is one of the most common monogenic 
disorders, caused by a point mutation in the sixth codon of the 
human β-globin gene.1 This multisystem disease is associated with 
severe episodes of acute illness and progressive organ damage.2 
While allogeneic hematopoietic stem cell transplantation (HSCT) 
may ameliorate SCD, it requires identification of an HLA-compatible 
donor and carries the risks of immunological complications of graft 
rejection and graft-versus-host disease.3 Autologous stem cell gene 
therapy is an alternative treatment without the limitations of allo-
geneic HSCT.
To date, several lentiviral vectors (LV) have been designed and suc-
cessfully used to target β-hemoglobinopathies in ex vivo modified 
hematopoietic stem cells (HSC) showing phenotypic correction of 
in vitro preclinical human models4–6 and in vivo murine models.4,7–12 
However, LV developed for the treatment of β-hemoglobinopathies 
require the presence of the β-globin introns,13,14 as well as the DNasel 
hypersensitive sites (HS) of the locus control region (LCR),15,16 which 
contain strong enhancers and regulatory elements to achieve suf-
ficient expression of the β-globin transgene. The combination of 
these elements yields a complex vector payload that may have a 
deleterious effect on the titer and transduction efficiency of the LV.
Moreover, the efficacy of these vectors may be still limited by 
transgene silencing due to DNA methylation and heterochromatini-
zation, as a consequence of chromosomal positional effects, which 
causes a lack of uniform and stable transgene expression. There are 
silencer sequences in the LV themselves, mainly located in the long 
terminal repeats (LTR), which also contribute to transgene silencing. 
Part of this problem was overcome by the deletions made in the 
3′LTR of the self-inactivating (SIN)-LV;17 however, there still may be 
residual silencing even from SIN-LTR.18,19
The inclusion of insulator sequences in LV has improved the 
expression problems. The addition of the 5′DNase I HS 4 of the 
chicken β-globin locus (cHS4, 1.2 kb) in the LTR of a β-globin LV was 
able to rescue chromosomal position effect, as shown by correction 
of the thalassemia phenotype in in vivo murine models.20 However, 
the strategy of placing relatively long insulator elements in both LTR 
still adversely affects titers and stability of the LV.21,22 Alternatively 
to the prototypic cHS4, other insulator elements with barrier activ-
ity have been identified, such as the DNase I HS immediately 5′ to 
the promoter of the human ankyrin-1 gene (ANK1). Gallagher et al.23 
demonstrated that this promoter region had structural and func-
tional characteristics of a barrier element in erythroid cells, and was 
able to prevent gene silencing in vivo.
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Ankyrin insulator sustains β-globin expression
Z Romero et al.
Lentiviral vectors designed for the treatment of the hemoglobinopathies require the inclusion of regulatory and strong enhancer 
elements to achieve sufficient expression of the β-globin transgene. Despite the inclusion of these elements, the efficacy of these 
vectors may be limited by transgene silencing due to the genomic environment surrounding the integration site. Barrier insula-
tors can be used to give more consistent expression and resist silencing even with lower vector copies. Here, the barrier activity of 
an insulator element from the human ankyrin-1 gene was analyzed in a lentiviral vector carrying an antisickling human β-globin 
gene. Inclusion of a single copy of the Ankyrin insulator did not affect viral titer, and improved the consistency of expression from 
the vector in murine erythroleukemia cells. The presence of the Ankyrin insulator element did not change transgene expression in 
human hematopoietic cells in short-term erythroid culture or in vivo in primary murine transplants. However, analysis in secondary 
recipients showed that the lentiviral vector with the Ankyrin element preserved transgene expression, whereas expression from the 
vector lacking the Ankyrin insulator decreased in secondary recipients. These studies demonstrate that the Ankyrin insulator may 
improve long-term β-globin expression in hematopoietic stem cells for gene therapy of hemoglobinopathies.
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Here we analyzed the potential barrier activity of a 159 bp frag-
ment of the 5′HS promoter region23 of the ANK1 (described from 
now on as “Ank insulator”) when placed in different orientations 
and sites within the previously described CCL-βAS3-FB LV.6 This 
promoter region included a point mutation in GATA-1 (ΔGATA-1) 
binding site to remove the enhancer activity; this point mutation 
was not expected to affect the barrier activity as described by 
Gallagher et al.23 In vitro clonal analysis of these constructs showed 
that a vector with a single copy of the Ank insulator in reverse ori-
entation with respect to the LV genome (Ank-R) was shielded from 
chromosomal position effect as effectively as by the cHS4 insulator. 
This Ank-R LV construct was then compared in vivo with the parental 
vector, showing a more consistent expression of the transgene in 
clonal assays and a significantly higher expression of the transgene 
and lack of silencing in long-term vector-transduced murine HSC.
ReSUlTS
Ankyrin-insulated lentiviral vector designs
We have shown that the CCL-AS3-FB LV (modified from CCL-βAS3, 
Figure 1a) is capable of efficient transduction of human SCD bone 
marrow (BM) CD34+ progenitor cells, and provides consistent 
expression of an antisickling β-globin gene reducing the percent-
age of sickling red blood cells (RBCs).6
To test the potential barrier activity of the 159 bp 5′HS region of 
the promoter of the ANK1 gene, the parental CCL-βAS3-FB LV (FB 
LV) (Figure 1b) was modified to include the Ank element. All of the 
constructs designed contained one copy of the synthetic FB insula-
tor placed in the 3′LTR of the parental FB LV. The FB element has 
been shown to exhibit the CTCF binding6 and functional activity of 
an enhancer-blocking insulator element, but does not have the bar-
rier activity.24 One construct was designed to carry one copy of the 
Ank sequence upstream of the β-globin LCR cassette (near the 3′ 
end of the vector), which is in reverse orientation relative to LV tran-
scription (Figure 1c) (Ank-R LV). In other constructs, a second copy 
of the Ank sequence was placed downstream of the βAS3-globin 
cassette (near the 5′ end of the vector), either in forward (Figure 1d) 
or reverse orientation (Figure  1e), (Ank-FR and Ank-RR LV, respec-
tively). The noninsulated version of the CCL-βAS3-FB LV was used as 
a negative control (Figure 1a) (AS3 LV) and a sixth vector including 
the large prototypic cHS4 insulator (Figure 1e) (cHS4 LV) was used 
as a positive control for a known insulator barrier activity.
The inclusion of the FB insulator in the 3′LTR did not modify the 
titer when compared with its noninsulated counterpart,6 neither did 
the addition of only one copy of the Ank insulator in reverse orienta-
tion (Ank-R). Instead, the inclusion of two copies of the Ank insula-
tor, independently of their orientation (Ank-FR and Ank-RR), had a 
deleterious effect on the LV titers. As expected, the insertion of the 
full-length cHS4 insulator made the titers drop more than 10-fold21 
(Supplementary Figure S1).
In vitro assessment of the insulator activity in clonal erythroid cells
To test for protection against chromosomal-position effects, indi-
vidual clones carrying only one copy of the vector were generated 
from pools of murine erythroleukemia (MEL) cells with each of 
the LV previously described. The parental CCL-βAS3-globin vector 
showed substantial variegation of expression, with 54.19 ± 17.02% 
of cells expressing the vector (Figure  2a). The clones carrying the 
Ank-R LV had a significantly higher percentage of cells expressing 
Figure 1 The proviral maps of the βAS3-globin vectors. The AS3 provirus has the βAS3-globin expression cassette including the human β-globin 
gene exons (arrow heads) with three amino acid substitutions to encode the βAS3-globin protein, introns and 3′ and 5′ flanking regions, the β-globin 
mini-LCR with hypersensitive sites 2–4, the mutated Woodchuck hepatitis virus post-transcriptional regulatory element (ΔWPRE) and the 3′SIN-LTR 
containing the FB insulator which is copied into the 5’LTR after reverse transcription. (a) AS3 LV, noninsulated version lacking the FB element; (b) CCL-
βAS3-FB parental vector (FB LV); (c) Ank-R LV includes one copy of the Ank insulator in the reverse orientation; (d) Ank-FR LV with two copies of the Ank 
insulator element flanking the expression cassette, one in forward and one in reverse orientation; (e) Ank-RR LV with two copies of the Ank insulator 
flanking the expression cassette, both in reverse orientation (all of the Ank-insulated LV retain the FB element); and (f) a positive control vector that 
includes a full-length copy (1.2 kb) of the cHS4 insulator in the 3′LTR that is copied to 5’LTR during reverse transcription.
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the βAS3-globin cassette (63.14 ± 10.99%) than: (i) those transduced 
with LV carrying two copies of the Ank insulator independently of 
their orientation (Ank-R versus Ank-FR, P  =  0.019) (Ank-R versus 
Ank-RR, P  =  0.028) (one-way analysis of the variance (ANOVA)) or 
(ii) those transduced with the parental FB LV (P = 0.022) (one-way 
ANOVA). The average percentage of expressing clones transduced 
with the Ank-R LV carrying one copy of the Ank insulator was equiv-
alent to the positive-control clones transduced with the cHS4 insu-
lator. The differences in expression between clones transduced with 
the LV insulated by the FB and noninsulated LV were not significant 
(one-way ANOVA).
No significant increase in the level of expression of the 
 βAS3-globin transgene was observed, when the Ank-insulated LV 
were compared with the AS3, FB, and cHS4 LV, (Figure 2b) (one-way 
ANOVA with multiple comparisons); the Ank element was expected 
to protect from chromosomal-position effects, but not to enhance 
the level of transgene expression. Further analyses were performed 
3 and 4 months post-transduction showing that, overall, a general 
silencing was observed in the clones of all the groups including 
the positive control (cHS4LV) and no significant differences were 
observed among groups (Figure 2c) (repeated-measure ANOVA).
The coefficient of variation (CV) of the βAS3-globin expres-
sion reflects the degree of expressing cells among clones with 
different integrations, and a lower CV indicates protection from 
 chromosomal-position effect. A higher percentage of expressing 
cells along with more homogenous expressions was observed in 
the clones transduced with the Ank-R LV and cHS4 LV, as indicated 
by their lower CV after 2 months in culture (Figure 2d). Moreover, 
the Ank-R LV maintained a lower CV with respect to all of the other 
LV analyzed, including the cHS4 LV (Figure 2d) demonstrating the 
barrier activity of the Ank insulator.
The instability of insulator elements in LV vectors has been previ-
ously reported;21 to address this possible concern and evaluate the 
Ank-insulator stability, PCR in 10 MEL cell clones with each of the LV 
constructs carrying this element were performed. In the case of the 
Ank-FR and Ank-RR, 30–50% of the clones analyzed did not show 
amplification for one or both copies of the Ank insulator (top and 
middle rows in Supplementary Figure S2a). However, when only 
Figure 2 Consistent expression of the βAS3-globin cassette in MEL cell clones carrying one copy of the Ank insulator. (a) The percentage of cells 
expressing βAS3-globin transgene was analyzed by flow cytometry after in vitro erythroid differentiation 2 months post-transduction. Each point 
represents one single vector copy/cell clone (AS3, n = 15; FB, n = 10; Ank-R, n = 11; Ank-FR, n = 11; Ank-RR, n = 8; and cHS4, n = 12). Bars represent average 
values for each group. One-way ANOVA with pairwise comparisons was used to compare the percentage of cells expressing βAS3-globin transgene 
between groups. The significance threshold used for P-value was 0.05. (b) Geometric mean of βAS3-globin expression of the samples shown in (a), and 
at the same time point. Bars represent average values for each group. No significant increase in the level of expression of the βAS3-globin transgene 
was observed due to the addition of the Ank insulator (one-way ANOVA with multiple comparisons, P > 0.05). (c) Mean values of the percentage of 
cells expressing βAS3-globin transgene. The average and SE of the mean (SEM) of the percentage of cells expressing βAS3-globin transgene measured 
in each group of clones at 2, 3, and 4 months post-transduction are summarized. No significant differences were observed among groups over time 
(repeated-measure ANOVA). (d) Percentage of the CV (%CV) of βAS3-globin expressing MEL cell clones over time. The %CV at each time point was 
calculated as the ratio of the SD to the average percentage of expressing cells of the clones of each group at each time point.
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one copy of the Ank insulator was present, it was transferred intact 
in all of the clones screened (bottom row in Supplementary Figure 
S2a). All the clones analyzed were positive for the PCR used to mea-
sure transduction, amplifying the packaging signal sequence (Psi) 
region common for all the constructs (Supplementary Figure S2b). 
The cHS4-insulator stability was analyzed in both LTR, showing that 
20% of the clones analyzed did not display amplification of the cHS4 
insulator in the 5′LTR (first panel in Supplementary Figure S2c).
In vitro assessment of the Ank-R LV activity in primary human 
CD34+ cells
The effect of the Ank insulator on βAS3-globin expression from the 
LV was examined in transduced primary human SCD BM CD34+ HSC 
differentiated into mature erythrocytes.6,25 BM-derived CD34+ cells 
from multiple SCD donors were either mock-transduced or trans-
duced with 2 × 107 TU/ml (multiplicity of infection (MOI) of 40) of 
the FB, Ank-R, and cHS4 LV. The average vector copy number (VCN) 
was comparable between the FB (1.2 ± 0.5) and Ank-R LV (1.0 ± 0.5) 
(P >0.01); however, the VCN was significantly reduced in cells trans-
duced with the cHS4 LV (0.1 ± 0.1; P ≤ 0.02), (Supplementary Figure 
S3a). The average percentage of  βAS3-globin mRNA per VCN was 
equivalent between the three LV (P > 0.05) (Supplementary Figure 
S3b). These data revealed no evidence of the Ank-element barrier 
activity in a bulk population of primary human cells in a short-term 
(3 weeks) in vitro culture.
Transgene expression in clonal progeny from murine HSC
In vivo colony-forming unit from spleen assay (CFU-S) was per-
formed to examine the expression of βAS3-globin transgene at 
a clonal level. BM from long-term primary recipients (at least five 
different mice per vector) were transplanted into each secondary 
recipient mouse (FB LV, n = 19; Ank-R LV, n = 11; and Mock, n = 5) for 
CFU-S analysis. CFU-S were harvested 10 days post-transplant (FB 
LV, 13 mice-produced colonies: n = 47; Ank-R LV, 7 mice-produced 
colonies: n = 36; and Mock, 2 mice-produced colonies: n = 5) for the 
VCN and gene-expression assessment. In the total secondary CFU-S 
analyzed, 91.5% (43/47colonies) contained the FB LV sequences 
and 97.2% (35/36 colonies) were positive for the Ank-R LV. The FB 
LV-treated colonies showed a greater variability and almost a two-
fold higher CV (62.9%) compared with the Ank-R colonies (36.7%), 
which showed a more homogeneous and consistent expression 
of the βAS3-globin transgene (Figure 3 and Table 1). For a further 
analysis of the clonal progeny, BM cells from long-term secondary 
mice were transplanted into tertiary recipients (FB LV, n = 14; Ank-R 
LV, n = 15; and Mock, n = 1). Tertiary CFU-S were harvested 10 days 
post-transplant (FB LV, 9 mice-produced colonies: n = 47; Ank-R LV, 
15 mice-produced colonies, n = 42; and Mock, 1 mouse-produced 
colony, n = 5), and samples were analyzed for VCN and βAS3-globin 
mRNA production. In the colonies analyzed from the tertiary trans-
plant recipients, 70.21 (33/47 colonies) and 66.67% (28/42 colonies) 
were positive for the FB and Ank-R LV proviruses, respectively.
Both LV presented a lower CV in tertiary CFU-S compared with the 
secondary ones: for the FB LV, the CV decreased from 62.9% in the 
secondary to 44.7% in the tertiary mice; and for the Ank-R LV, the CV 
dropped from 36.7% in the secondary mice to 23.7% in the tertiary 
mice (Figure 3 and Table 1). However, as with the secondary CFU-S, 
the tertiary CFU-S from the FB LV-treated mice had a wider distribu-
tion of the percentage of transgene expression, resulting in more than 
a twofold higher SD, and therefore a CV that was 1.8 times greater 
than in the Ank-R LV mice. These results demonstrate the propensity 
of the Ank-R LV to protect from position-effect variation, providing a 
more stable and consistent expression of the βAS3-globin transgene.
In vivo expression of the βAS3-globin transgene by FB versus 
Ank-R LV
With the aim of analyzing gene expression in long-term murine HSC, 
primary and secondary transplants were carried out. Lineage nega-
tive cells from BM from CD45.1 (+) B6.SJL-Ptprca Pep3b/BoyJ male 
donor mice were transduced with the Ank-R LV and transplanted 
into congenic CD45.2 (+) C57bl/6J female mice and compared with 
mice transplanted with the cells transduced with the parental FB 
LV. VCN from transduced BM cells cultured in vitro for 2 weeks was 
2.4 ± 0.2 for the FB LV and 2.6 ± 0.1 for the Ank-R LV, from two inde-
pendent transductions.
Engraftment in blood was above 90% at 10 weeks post-transplant 
in all primary mice (Supplementary Figure S4a). VCN in blood sam-
ples was measured periodically every 3 weeks up to 20 weeks, show-
ing stable and efficient gene transfer, without differences between 
vectors (repeated-measure ANOVA) (Supplementary Figure S5a). 
βAS3-globin mRNA expression was analyzed simultaneously from 
blood samples obtained for VCN analysis. The percentage of the 
βAS3-globin mRNA transcripts relative to the murine β-globin-like 
mRNA transcripts (“percentage of the βAS3-globin mRNA”) per VCN 
in blood of the primary recipients did not differ between groups 
(Supplementary Figure S5b) at any of the time points analyzed 
(repeated-measure ANOVA). Primary mice were euthanized 20 
weeks post-transplant to perform secondary transplants. No differ-
ences were observed in engraftment, VCN, and βAS3-globin mRNA 
expression in the BM from the primary mice, as was observed in 
Figure 3 Transgene expression in clonal progeny from murine HSC. 
Percentage of βAS3-globin mRNA normalized per VCN from CFU-S in 
secondary and tertiary recipients harvested 10 days post-transplant. 
Bars represent average values for each group and SD. The percentage of 
CV (%CV) shown at the bottom of the graph was calculated as the ratio 
of the SD to the mean of βAS3-globin levels per VCN from the clones in 
each group.
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blood samples. The engraftment of donor cells in BM from primary 
mice ranged from 70 to 99% (Supplementary Figure S4b), and the 
VCN values were 2.03 ± 1.03 and 2.09 ± 1.14 for the FB LV and Ank-R 
LV, respectively; and the average expression of the βAS3-globin 
mRNA normalized to the VCN was 3.45 ± 1.47% and 4.85 ± 1.97% for 
the FB-LV and Ank-R LV, respectively (Supplementary Figure S6).
Secondary mice were euthanized 11 weeks post-transplant. High 
levels of engraftment were observed in blood and BM in the three 
groups of mice (Supplementary Figure S7). The blood samples 
were analyzed to determine gene marking in the two groups FB LV 
(0.96 ± 0.64) and Ank-R LV (0.84 ± 0.95) and no difference was seen 
in the two groups (P >0.05, two-sample t-test) (Figure 4a). However, 
the gene-expression values (βAS3-globin mRNA/VCN) were statisti-
cally higher in the Ank-R LV group compared with the FB LV group 
(P = 0.001, two-sample t-test) (Figure 4b). We observed that the βAS3-
globin transgene expression per VCN declined in the FB LV group 
significantly (P = 0.01, two-sample t-test), from 24.76 ± 25.30% βAS3-
globin mRNA/VCN in primary mice to 6.92 ± 6.05%  βAS3-globin 
mRNA/VCN in secondary mice. In contrast, no significant differences 
were observed in the βAS3-globin transgene expression per VCN 
between primary (28.13 ± 14.64% βAS3-globin mRNA/VCN) and sec-
ondary mice (32.68 ± 31.09% βAS3-globin mRNA/VCN) for the Ank-R 
LV-treated group (P = 0.7, two-sample t-test). These results suggest 
that the inclusion of the Ank insulator protected long-term expres-
sion of the βAS3-globin cassette from silencing (Figure 4c).
Similar results were obtained with BM samples from the second-
ary mice. There were no differences in gene transfer between the 
FB and Ank-R LV-treated groups (Figure 5a). However, the expres-
sion levels of the FB LV were significantly lower than the expression 
levels of the Ank-R LV (P  <  0.001, two-sample t-test) (Figure  5b). 
When the transgene expression was compared between BM of 
primary and secondary mice, the same pattern as in blood was 
observed. The expression of the βAS3-globin transgene was main-
tained between primary (4.85 ± 1.97% βAS3-globin mRNA/VCN) 
and secondary mice (3.74 ± 2.06% βAS3-globin mRNA/VCN) in the 
Ank-R LV group (showing no significant differences P  =  0.2, two-
sample t-test), but was significantly lower in the secondary mice of 
the FB LV group (1.43 ± 1.36% βAS3-globin mRNA/VCN), compared 
with the primary mice (3.45 ± 1.47% βAS3-globin mRNA/VCN) 
(P = 0.002, two-sample t-test) (Figure 5c).
The expression of the vectors was also analyzed at the protein 
level by measuring AS3 hemoglobin (HbAS3) production in blood, 
by high-performance liquid chromatography (HPLC). The higher 
percentage of βAS3-globin mRNA produced per VCN by the Ank-R 
Figure 4 Long-term assessment of VCN, βAS3-globin mRNA, and HbAS3 expression in peripheral blood from secondary mice. (a) VCN analyzed in 
blood samples 11 weeks post-transplant. No differences in VCN were found between mice treated with the two different LV (P = 0.65, two-sample 
t-test). (b) Percentage of βAS3-globin mRNA per VCN from the samples shown in (a). Expression values were higher in the group of mice treated 
with Ank-R LV (P = 0.001, two-sample t-test). (c) The percentages of βAS3-globin mRNA per VCN, expressed in the primary and secondary mice 
at week 20 and 11 post-transplant, respectively, were analyzed for each LV (two-sample t-test). FB LV: primary mice, n = 9 and secondary, n = 18; 
for Ank-R LV-treated mice: primary, n = 8 and secondary, n = 21. The data shown in this graph at week 20 of the primary mice correspond to the 
average values shown in Supplementary Figure S5b; and the data shown at week 11 for the secondary mice are the same graphed in this panel in 
4(b). (d) HPLC of blood samples from secondary recipients at week 11 post-transplant for hemoglobin tetramers analysis. The relative percentage 
of HbAS3 produced for each sample was calculated based on the sum total of areas under the curve for each of the primary hemoglobin peaks 
which included βmajor and βminor. Protein production was higher in the group of mice treated with Ank-R LV (P = 0.002, two-sample t-test). 
Bars represent average values and SD.
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LV corresponded with a significantly higher production of HbAS3 
protein per VCN (P = 0.002, two-sample t-test) (8.12 ± 7.77% HbAS3), 
compared with FB LV samples (2.13 ± 1.55% HbAS3) (Figure  4d). 
These results confirm that one copy of the Ank insulator in reverse 
orientation in the CCL-βAS3-FB LV protects the expression of the 
transgene from silencing in the long-term transduced HCS.
DISCUSSION
Chromosomal-position effects on gene expression have a critical 
impact in LV-based gene therapy due to the semirandom pattern 
of integration of these vectors. If the integration of the vectors hap-
pens within or near heterochromatin areas, the level and pattern of 
expression of the transgene of interest can be negatively affected.26 
Barrier insulators are defined as heterochromatin boundaries as 
they block the spread of the heterochromatin; addition of bar-
rier elements to LV constructs may protect from heterochromatin 
formation in the provirus, leading to a more stable and consistent 
expression.
We have analyzed the potential capacity of the insulator from the 
5’HS promoter region of the human ANK1 gene to provide a more 
stable and homogenous expression from the parental CCL-βAS3-FB 
LV previously described by our group.6 Breda et  al.27 showed that 
in the context of a β-globin LV, a 190 bp fragment of the ANK1 pro-
moter, when included in both LTR, was able to maintain phenotypic 
correction in β-thalassemic mice, at least to the same levels as its 
counterpart noninsulated LV. However, in all of the new constructs 
we designed, the Ank insulator was placed within the  βAS3-globin 
cassette with the aim of keeping the Ank element flanked by the 
enhancer-blocking FB insulator, included in both LTR of the provirus. 
With this design, the genes surrounding the proviral integration site 
would be protected by the FB insulator from any residual enhancer 
activity from the Ank fragment. The stability of the Ank sequence in 
the different constructs was analyzed, indicating that the presence 
of more than one copy of the insulator led to the loss of one or both 
of these sequences. A potential explanation for the loss of the insula-
tor would be deletion during reverse transcription or homologous 
recombination after the reverse transcription; however further analy-
sis would be necessary to fully understand these events.
Protection against position-effect variegation was observed 
in MEL clones only when a single copy of the Ank insulator was 
used. But, after 4 months in culture, the clones from all of the LV 
analyzed, including the ones containing the full cHS4 insulator, 
showed a dramatic loss of expression. This could be a result of the 
loss of differentiation capacity of the erythroleukemia cell line 
used for this assay after extended culture. Therefore, the Ank-R 
LV was compared with the FB and cHS4 LV in human primary 
cells. However, the in vitro assessment of the barrier activity of 
the Ank-R LV in cells from SCD BM donors was not conclusive, as a 
result of the short duration of the erythroid differentiation of the 
bulk population analyzed.
Figure 5 Long-term assessment of VCN and βAS3-globin mRNA expression in BM from secondary mice. (a) VCN analyzed in BM samples 11 weeks 
post-transplant. No differences in VCN were found between mice treated with the two different LV (P = 0.50, two-sample t-test). (b) Percentage of βAS3-
globin mRNA per VCN from the samples shown in (a). Expression values were higher in the group of mice treated with Ank-R LV (P < 0.001, two-samples 
t-test). (c) The percentages of βAS3-globin mRNA expressed in the primary and secondary mice at week 20 and 11 post-transplant, respectively, were 
analyzed for each LV (two-sample t-test). FB-LV treated mice: primary mice, n = 9 and secondary mice, n = 18; Ank-R LV-treated mice: primary, n = 8 and 
secondary, n = 21. The data shown in this graph at week 20 for the primary mice correspond to the average values shown in Supplementary Figure S6, 
(right y-axis); and the data shown at week 11 for the secondary mice are the same as graphed in this panel in 5(b). Bars represent average and SD values.
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Chromosomal-position-effect variegation therefore was evalu-
ated in vivo in CFU-S from secondary and tertiary mice, which 
provides a more stringent assay for expression in the products of 
long-term HSC than short-term cultures and primary transplants do. 
The consistent level of expression of the βAS3-globin transgene per 
VCN in the Ank-R LV group, compared with the wide range of expres-
sion of the transgene per VCN in the FB LV group, indicates that the 
Ank insulator is able to provide a more  position-independent expres-
sion of the βAS3-globin transgene. The HS3 fragment of the β-globin 
gene LCR has been shown to be able to provide an open chroma-
tin environment appropriate to confer copy number-dependent 
gene expression in transgenic mice;28,29 however, only the whole 
LCR is able to recruit the erythroid-specific transcription factors and 
histone-modifying complexes necessary to confer a full barrier activ-
ity.16 Thus, the current mini-LCR used in globin vectors may not be 
able to provide the optimal chromatin architecture necessary to 
confer position independence. Therefore, the addition of the Ank 
sequence upstream of the mini-LCR in the FB-LV might be respon-
sible for recruiting transcription factors such as USF1/2 (ref. 23) that 
directly interacts with HAT and HMT maintaining high levels of H3 
acetylation and K4 methylation as shown with the cHS4 insulator.30
The protection against position-effect variegation observed at a 
clonal level in the Ank-R LV group correlated with a lack of silencing 
in long-term vector-transduced HSC in serial transplants in the Ank-R 
LV-treated mice. The main difference between the vectors with and 
without the Ank insulator was observed in the transgene expression in 
blood in secondary mice, where the Ank-R LV provided a significantly 
higher percentage of expression of the  βAS3-globin transgene per 
VCN, at both the mRNA and protein levels. Additionally, the average 
percentages of βAS3-globin mRNA per VCN in both primary and sec-
ondary mice from the Ank-R LV group were very consistent and sus-
tained, showing no silencing of the βAS3-globin cassette. In contrast, 
the expression levels of the  βAS3-globin transgene in the secondary 
mice treated with the FB LV were significantly lower compared with 
the primary mice of this group. The same pattern of mRNA expression 
per VCN was observed in the BM samples from secondary mice.
When initially describing the Ank element, Gallagher et al.23 dem-
onstrated the enrichment for USF1/2 transcription factors and histone 
markers associated with open chromatin, thus following a model for 
barrier insulator activity in which proteins are recruited to block the 
spread of heterochromatin. Our data follow this model as the addi-
tion of the Ank insulator to the CCL-AS3-FB LV promoted in vitro and 
in vivo protection from chromosomal-effect variegation with a lower 
CV of the βAS3-globin transgene expression per VCN. In addition, the 
Ank insulator helped to maintain the expression of the βAS3-globin 
transgene per VCN at the RNA level, which was correlated with higher 
HbAS3 protein production in long-term secondary mice.
These data together indicate that the addition of the Ank insulator 
protects the βAS3-globin expression cassette from  positional-effect 
variegation and long-term silencing after transduction of primi-
tive murine HSC. Further analyses in murine SCD models will allow 
assessment of whether the addition of the Ank element to the 
 CCL-AS3-FB LV significantly improves inhibition of sickling in a clini-
cally beneficial manner.
MATeRIAlS AND MeTHODS
βAS3-globin lentiviral vectors construct, packaging, and titer 
determination
The CCL-βAS3, CCL-βAS3-FB, and CCL-βAS3-cHS4 LV were previously 
described.6 Briefly, the LV carrying the Ank insulator were cloned as follows. 
Ank-dGATA1 top and bot deoxyoligonucleotides (see sequences below) were 
annealed and made double stranded with Pfu Ultra II HS Polymerase (Agi-
lent, Santa Clara, CA). For Ank insertion at the 3′ end of the globin cassette 
next to the 3′ genomic enhancer, pCCLc-AS3-dWPRE-FB was linearized with 
EcoRV and dephosphorylated with Antarctic phosphatase (New England 
Biolabs, Ipswich, MA). Blunt-end ligation was carried out with this linearized 
vector and the annealed, double-stranded Ank cassette, and clones were 
screened for single-cassette insertion and proper orientation. For Ank inser-
tion at the 5′ end of the globin cassette next to the HS4 sequence of the mini-
LCR, pCCLc-AS3-dWPRE-FB was cut with MfeI (New England Biolabs, Ipswich, 
MA), and the large and small fragments were gel purified. The large fragment 
was religated, and the resulting plasmid was then digested with EcoRI (New 
England Biolabs), blunted, and dephosphorylated. The blunt-end ligation 
was carried out with this linear vector and the Ank cassette, and clones were 
screened for single-cassette insertion and proper orientation. The smallest of 
the gel-purified MfeI fragments was then reinserted to generate the full AS3 
vector with desired Ank sequences.  Ank-dGATA1-top /5Phos/TGGGGAGC-
GGGGCC TCC TGGGGT TGGGGGAGGAGGTGC TC T TGTAATC TGCGGT 
CCCCAGGCGGGCGCCACCCCTCCGCCCGCCCGTGCC Ank-dGATA1-bot /5Phos/
GACGTGCGGGCCAGGCCCCCGAGGGCCTTAACGGCCCCAGAGGCGCTTGCT-
GTCGGGCCGGGCGCTCCCGGCACGGGCGGGCGGAGGGGT.
 Small-scale production of the different LV and titering were performed 
as previously described.6 Large-scale viral preparations were produced 
and concentrated using tangential flow filtration and titered by qPCR as 
described previously.31
MEL cells culture, erythroid differentiation, and intracellular  
 βAS3-globin staining for flow cytometry
MEL cells (ATCC number TIB-56, Manassas, VA) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Mediatech, Herndon, VA) containing 1× 
glutamine, penicillin, and streptomycin (both from Cellgro, Manassas, VA) 
and 10% fetal bovine serum (FBS) (Gemini Bio-Products, West Sacramento, 
CA). Single-vector copy MEL cell clones were generated for subsequent 
expression analyses by transducing with each LV at low MOI (from 0.2 to 2). 
One week post-transduction, single cells were sorted from the pools using 
the fluorescence-activated cell sorting (FACS)-automated cell deposition 
unit (ACDU) technique into wells containing DMEM-10% FBS. After sorting, 
the MEL cell clones were expanded and characterized for the presence or 
absence of vector by PCR with primers amplifying the Psi region common to 
all the vectors. The PCR reaction was started at 94°C for 1 minute, followed by 
35 cycles of 98°C for 5 seconds, 62°C for 5 seconds, and 72°C for 5 seconds, 
using an Eppendorf Mastercycler Pro S (Eppendorf, Hamburg, Germany). The 
resulting PCR product was loaded in a 2% agarose (BioExpress, Kaysville, UT) 
gel and run in 1× TAE (Cellgro, Manassas, VA) for a qualitative analysis of trans-
duced MEL cell clones. Four weeks post-transduction, cells from each MEL 
cell clone containing at least one copy of an LV (as determined by PCR for Psi) 
were harvested for genomic DNA isolation using the PureLink Genomic DNA 
Mini Kit (Invitrogen, Carlsbad, CA) to identify those clones containing single-
vector copies. The average VCN was determined by two separate qPCR reac-
tions: one specific for the HIV-1 Psi in the LV provirus, and the other specific 
for the housekeeping gene UC483 present at consistent levels in the MEL cell 
line. The Psi signal was normalized to the amount of UC483 amplified to cal-
culate the average number of VCN per cell in each transduced MEL cell clone 
based on a standard curve method described by Cooper et al.31
For in vitro erythroid differentiation, 2.5 × 105 MEL cells/ml were cultured 
in DMEM with 20% FBS, supplemented with 5 mmol/l N,N’-hexamethylene 
bisacetamide (HMBA) (Sigma-Aldrich, St. Louis, MO). After 5 days of differ-
entiation, 1–3 × 106 MEL cells were harvested for intracellular staining with 
an anti-human β-globin antibody to assess the level of βAS3-globin expres-
sion. The cells were stained with the viability dye Aqua Dead Cell Stain (Life 
Technologies, Grand Island, NY) for 15 minutes, prior to fixation with 4% 
paraformaldehyde (USB Corporation, Cleveland, OH) for 1 hour, and subse-
quently with 100% methanol for 5 minutes (Sigma-Aldrich). Following fixa-
tion, the cells were blocked with 5% non-fat milk (Santa Cruz Biotechnology, 
Dallas, TX), and then stained with a PE-labeled anti-human β-globin antibody 
(Hemoglobin β(38-7) sc-21757, Santa Cruz Biotechnology, Santa Cruz, CA) in 
the presence of Fix & Perm Solution B (Life Technologies, Carlsbad, CA) for 
30 minutes. All of the flow cytometry analyses were performed on an LSR 
Fortessa cell analyzer (BD Biosciences, San Jose, CA).
The CV was calculated as the ratio of the SD to the average percentage of 
expressing cells of the clones of each group at each time point.
Stability of the insulators
The integrity of the Ank insulator was analyzed by PCR in MEL clones that 
were transduced with the three different LV carrying the Ank insulator in 
diverse positions and orientations. Genomic DNA isolation was performed 
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using the PureLink Genomic DNA Mini Kit (Invitrogen). Two set of primers 
were designed to amplify the Ank sequence upstream from the β-globin LCR 
cassette (near the 5′ end of the vector), one set to amply the Ank insulator 
in forward orientation (Ank-F: Forward: 5′-AGT TTG GGT CGA GGA TTG GGG 
AGC-3′ and Reverse: 5′-GAA TTC CGA TCC GAT GAC GTG CGG G-3′, with an 
expected band of 190 bp) and a second set to amplify the Ank insulator in 
reverse orientation (Ank-R5’: Forward: 5′-GGG TCG AGG ATG ACG TGC GGG 
CCAG G 3′ and _Reverse: 5′-GAG AAT TCC GAT CCG ATT GGG GAG C-3′, with 
an expected band of 187 bp). A third set of primers was designed to amplify 
the Ank insulator located downstream of the β-globin LCR cassette (near the 
3′ end of the vector), and placed in reverse orientation (Ank-R3′: _Forward: 
5′-CGA GGG AAT TGA CGT GCG and Reverse: 5′- TTG ATT ATC GGA ATT TGG 
GGA GCG GGG C-3′, in this case the corresponding amplicon had a length of 
183 bp). The stability of the cHS4 insulator was tested as well by PCR in MEL 
clones that were transduced with the LV carrying this insulator. In this case, the 
primers used were the following ones. To amplify the cHS4 sequence in the 
5’LTR of the provirus: F-5LTR-FB: 5′-GGCTAATTCACTCCCAACGAAGACAAG-3′ 
and R-5LTR-FB: 5′-CTT CAG CAA GCC GAG TCC TGC-3′. To amplify the cHS4 
sequence in the 3′LTR of the provirus: F- 3′LTRcHS4: 5′-CTG CAG ATA TCC ATC 
ACA CTG GCG G-3′ and R-3LTR-FB: 5′-CAG AGA GAC CCA GTA CAA GCA AAA 
AG-3′. PCR were executed using Taq DNA Polymerase, Native (Invitrogen) on 
an Eppendorf (Hamburg, Germany) thermocycler. The PCR products were 
visualized by GelGreen (Phenix Research Products, Candler, NC) on 2% aga-
rose gels.
Human CD34+ cell isolation, transduction, erythroid differentiation, 
and VCN and mRNA analysis
Isolation of human CD34+ cells from BM, transduction, and in vitro ery-
throid differentiation were performed as described by Romero et  al.6 
Bone marrow aspirates from volunteer donors with SCD were obtained 
under UCLA IRB# 001399.
Isolation, transduction, and transplantation of murine HSCs
BM cells from femurs and tibias from untreated 8-week-old male CD45.1 
(+) B6.SJL-Ptprca Pep3b/BoyJ (C57L/6 congenic) (Jackson Laboratories, Bar 
Harbor, ME) donor mice were harvested, lineage depleted using the Lineage 
Cell Depletion Kit (Miltenyi Biotech, Bergisch Gladbach, Germany) and linage 
negative (lin-)cells were cryopreserved. Forty hours prior to transplant, lin- 
cells were thawed and prestimulated in StemSpan SFEM serum-free expan-
sion medium (STEMCELL Technologies, Vancouver, British Columbia, Canada) 
containing 50 ng/ml mSCF, 100 ng/ml human interleukin (IL)-11, 20 ng/ml 
mIL-3 (all PeproTech, Rocky Hill, NJ), 100 ng/ml hFlt3-L (Celldex Therapeutics, 
Needham, MA), and 1× glutamine, penicillin and streptomycin in plates coated 
with retronectin (20 μg/ml; Clontech, Mountain View, CA). After 16 hours of 
prestimulation, transductions with the FB and Ank-R LV were performed at the 
concentration of 2 × 107 TU/ml (MOI ~80).  Tewnty-four hours post-transduc-
tion, the cells were harvested, counted, and 106 lin- cells were transplanted into 
8-week-old female CD45.2 (+) C57bl/6J recipients (Jackson Laboratories) after 
total body irradiation (10.75 Gy split into two doses separated by 3 hours). 
Primary mice were maintained up to 4 months and retro-orbital bleeds were 
performed periodically for VCN and β-globin mRNA analysis.
Mice harvest and secondary transplants
Four months after transplants, BM cells from femurs and tibias of primary 
recipients were harvested. Portions of the marrow were used to determine 
engraftment by FACS, and for VCN and mRNA analyses. Prior to euthana-
sia, retro-orbital bleeds were performed as well for engraftment, VCN, and 
mRNA from blood analysis at that last time point. For long-term analyses of 
gene expression and silencing, 20 × 106 cells of whole BM cells were trans-
planted into each secondary recipient. Secondary mice were euthanized 
after 11 weeks for final analysis of engraftment, VCN, and βAS3-globin mRNA 
in blood and BM. All work with mice was done under protocols approved by 
the UCLA Animal Research Committee.
Spleen colony-forming units (CFU-S)
For vector expression analyses in clonal progeny from murine HSC, 1 × 106 
whole BM cells from primary and secondary mice were transplanted in 
multiple CD45.2 female recipients. Individual CFU-S (secondary and ter-
tiary) were isolated by dissection from spleens collected 10 days after 
transplants. Each CFU-S was divided in two halves, for genomic DNA isola-
tion (PureLink Genomic DNA Mini Kit, Invitrogen) for VCN determination 
and for RNA isolation (RNeasy Plus Mini Kit, Qiagen, Valencia, CA) for βAS3-
globin mRNA expression assay.
Engraftment assessment
Donor-recipient chimerism was determined in blood and BM samples 
from primary and secondary recipients by FACS. Samples were incubated 
at 4°C for 5 minutes with rat anti-mouse CD16/CD32 antibody to block Fc 
receptors, prior to addition of APC-conjugated mouse anti-mouse CD45.2 
and  V450-conjugated mouse anti-mouse CD45.1 (all antibodies from BD 
Biosciences) followed by incubation at 4°C for 30 minutes. Antibody excess 
was washed out with PBS and samples were analyzed with a LSR Fortessa 
cell analyzer (BD Biosciences). The percentage of engrafted donor cells was 
defined as follows: %CD45.1+/(%CD45.1+ + %CD45.2+).
DNA analysis
Genomic DNA isolations from blood samples and BM samples were per-
formed using the NucleoSpin Tissue XS kit (Clontech) and the PureLink 
Genomic DNA Mini Kit (Invitrogen), respectively, and according to manufac-
turer’s instructions.
For VCN determination, primers and probe were designed to 
detect a conserved LV sequence (HIV-1 Psi region)  (Forward-HIVU5: 
5′-AAGTAGTGTGTGCCCGTCTG-3′;  Reverse-HIV-Psi:5′-CCTCTGGTTTCCCTTT 
CGCT-3′ and probe:  5′-/5HEX/CCCTCAGAC/ZEN/CCTTTTAGTCAGTGTGGAA
AATCTCTAG/3IABkFQ/-3′) and Y-chromosome-specific primers and probe 
(Mm00527143_cn) (purchased as a 20× premix of primers and FAM-MGBNFQ 
probe; Applied Biosystems, San Francisco, CA) were used for normaliza-
tion. Reaction mixtures of 20 μl volume comprising 1× ddPCR Master Mix 
(Bio-Rad, Hercules, CA), primers, and probe (900 nmol/l and 250 nmol/l for 
Y-chromosome primers and probe respectively; 500 nmol/l and 100 nmol/l 
for Psi primers and probe, respectively) were used. Droplet generation was 
performed as described in Hindson et  al.32 PCR amplification of droplet 
emulsion, droplet read, and ddPCR analysis were performed as previously 
described.6 VCN of donor cells was calculated by dividing the concentration 
(copies/μl) of Psi by the concentration of Y-chromosome.
RNA analysis
RNA from BM samples was extracted using the RNeasy Plus Mini Kit (Qiagen) 
according to the manufacturer’s instructions. Blood samples for RNA analysis 
were collected in RNAprotect Animal Blood Tubes (Qiagen) and incubated 
at room temperature for 2 hours, prior to RNA isolation with RNeasy Protect 
animal Blood Kit (Qiagen). In both cases, first-strand cDNA was synthe-
sized using random primers, M-MLV reverse transcriptase, and RNAseOUT 
Recombinant Ribonuclease Inhibitor (all from Invitrogen) according to the 
manufacturer’s protocol.
To specifically detect βAS3-globin mRNA transcripts originating from 
the vector CCL-βAS3-FB, a set of primers and probe, previously described 
(HBBAS3),6 were used together with a second set of primers and probe 
designed to amplify the murine single haplotype β-like transcripts 
(Forward-murine β-glo 5′-TGCTGGTTGTCTACCCTTGGAC-3′; Reverse-murine 
β-glo 5′-TCGTTAAAGGCAGTTATCACTTTCTTGC-3′ and probe: 5′/5HEX/
CCTATCCTC/ZEN/TGCCTCTGCTATCATGGGTAATGCCAAAGT/3IABκF) (all 
primers were used at a final concentration of 500 nmol/l and probes at 100 
nmol/l). ddPCR was performed as described6 and the relative expression of 
βAS3-globin/murine β-globin-like was calculated by dividing the concentra-
tion (copies/μl) of βAS3-globin by the concentration of murine β-globin-like, 
and normalizing to the VC/cell measured for each sample.
High-performance liquid chromatography (HPLC)
Secondary mice were bled 11 weeks post-transplant. One microliter of periph-
eral blood per was lysed as follows. RBC were pelleted and lysed in Hemolysate 
reagent (Helena Laboratories, Beaumont, TX) for 5–10 minutes at room tem-
perature. After centrifugation at 20,800g for 10 minutes at 4°C to remove cel-
lular debris, RBC lysates were stored frozen at −80°C. Upon thawing, cell lysates 
were diluted 1:40 in mobile phase A and characterized by HPLC (Infinity 1260, 
Agilent) using a weak cation-exchange column (PolyCAT A, PolyLC, Coulmbia, 
MD). FASC Reference Material (Trinity Biotech, Wicklow, Ireland) was used to 
define the elution time of common human hemoglobin forms (HbF, HbA, 
HbS, and HbC). Analysis and peak integration were performed using OpenLAB 
CDS Chemstation software (Agilent, Santa Clara, CA). The relative percentage 
of HbAS3 produced for each sample was calculated based on the sum total 
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of areas under the curve for each of the primary hemoglobin peaks, which 
included βmajor and βminor.
Statistical analysis
Descriptive statistics such as number of observations, mean and SD were 
reported and presented graphically for quantitative measurements. 
Normality assumption was checked for outcomes before statistical test-
ing. For both primary and secondary mice, comparisons of expression (i.e., 
VCN, percentage of βAS3-globin mRNA/VCN, and percentage of HbAS3/
VCN) and engraftment in BM and blood between experimental groups 
were performed by either two-sample t-tests (Figure 4a–d; Figure 5a–c and 
Supplementary Figure S6) or one-way ANOVA33 with pairwise comparisons 
(Figure  2a,b; Supplementary Figure S3a,b; Supplementary Figure S4a,b; 
Supplementary Figure S7a,b). Repeated-measure ANOVA34 was used to 
assess if there was treatment group difference in βAS3-globin expression 
in MEL cell clones (Figure 2c) or in blood over time (Supplementary Figure 
S5a,b). All hypothesis testing was two-sided and a significance threshold of 
0.05 for P-value was used. Analyses were carried out using SAS version 9.3 
(SAS Institute, Cary, NC).35
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